157 related articles for article (PubMed ID: 33304848)
41. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
[TBL] [Abstract][Full Text] [Related]
42. Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up.
Minatel E; Trovo M; Polesel J; Baresic T; Bearz A; Franchin G; Gobitti C; Rumeileh IA; Drigo A; Fontana P; Pagan V; Trovo MG
Lung Cancer; 2014 Jan; 83(1):78-82. PubMed ID: 24216141
[TBL] [Abstract][Full Text] [Related]
43. Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP).
Rojas L; Cardona AF; Trejo-Rosales R; Zatarain-Barrón ZL; Ramírez-Tirado LA; Ruiz-Patiño A; Campos Gómez S; Corrales L; Oblitas G; Bacon L; Martín C; de Lima VCC; Freitas HC; Mas L; Vargas C; Carranza H; Otero J; Pérez MA; González L; Chirinos L; Granados ST; Rodriguez J; Báez R; Remolina Bonilla YA; Núñez Cerrillo G; Archila P; Cuello M; Karachaliou N; Rosell R; Arrieta O;
Thorac Cancer; 2019 Mar; 10(3):508-518. PubMed ID: 30706690
[TBL] [Abstract][Full Text] [Related]
44. Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: the outcome of incomplete resections.
Bölükbas S; Eberlein M; Fisseler-Eckhoff A; Schirren J
Lung Cancer; 2013 Aug; 81(2):241-6. PubMed ID: 23688589
[TBL] [Abstract][Full Text] [Related]
45. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
Scagliotti GV; Gaafar R; Nowak AK; Reck M; Tsao AS; van Meerbeeck J; Vogelzang NJ; Nakano T; von Wangenheim U; Velema D; Morsli N; Popat S
Clin Lung Cancer; 2017 Sep; 18(5):589-593. PubMed ID: 28690011
[TBL] [Abstract][Full Text] [Related]
46. A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years' Experience.
Opitz I; Friess M; Kestenholz P; Schneiter D; Frauenfelder T; Nguyen-Kim TD; Seifert B; Hoda MA; Klepetko W; Stahel RA; Weder W
J Thorac Oncol; 2015 Nov; 10(11):1634-41. PubMed ID: 26317916
[TBL] [Abstract][Full Text] [Related]
47. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
[TBL] [Abstract][Full Text] [Related]
48. Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions.
Larose F; Quigley N; Lacasse Y; Martel S; Lang-Lazdunski L
Lung Cancer; 2021 Jun; 156():151-156. PubMed ID: 33962765
[TBL] [Abstract][Full Text] [Related]
49. Pleurectomy/decortication and hyperthermic intrathoracic chemoperfusion using cisplatin and doxorubicin for malignant pleural mesothelioma.
Klotz LV; Lindner M; Eichhorn ME; Grützner U; Koch I; Winter H; Kauke T; Duell T; Hatz RA
J Thorac Dis; 2019 May; 11(5):1963-1972. PubMed ID: 31285889
[TBL] [Abstract][Full Text] [Related]
50. Non-incisional pleurectomy/decortication for malignant pleural mesothelioma.
Tanaka F; Takenaka M; Imanishi N; Hirai A; Kanayama M; Mori M; Matsumiya H; Taira A; Shinohara S; Kuroda K
Gen Thorac Cardiovasc Surg; 2021 Sep; 69(9):1320-1325. PubMed ID: 34028663
[TBL] [Abstract][Full Text] [Related]
51. Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors.
Minatel E; Trovo M; Bearz A; Di Maso M; Baresic T; Drigo A; Barresi L; Furlan C; Del Conte A; Bruschi G; Fontana P; Pagan V; Franchin G
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):606-13. PubMed ID: 26281826
[TBL] [Abstract][Full Text] [Related]
52. Locoregional control and toxicity after pleurectomy/decortication and intensity-modulated pleural radiation therapy in patients with malignant pleural mesothelioma.
Arrieta O; Lozano-Ruiz F; Blake-Cerda M; Catalán R; Lara-Mejía L; Salinas MÁ; Maldonado-Magos F; Corona-Cruz JF
Thorac Cancer; 2020 Dec; 11(12):3448-3455. PubMed ID: 33030313
[TBL] [Abstract][Full Text] [Related]
53. How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?
Sharkey AJ; O'Byrne KJ; Nakas A; Tenconi S; Fennell DA; Waller DA
Lung Cancer; 2016 Oct; 100():5-13. PubMed ID: 27597274
[TBL] [Abstract][Full Text] [Related]
54. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
[TBL] [Abstract][Full Text] [Related]
55. Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date.
Levin PA; Dowell JE
Onco Targets Ther; 2017; 10():2057-2066. PubMed ID: 28435296
[TBL] [Abstract][Full Text] [Related]
56. Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.
Marquez-Medina D; Popat S
Clin Transl Oncol; 2016 Aug; 18(8):760-8. PubMed ID: 26680633
[TBL] [Abstract][Full Text] [Related]
57. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ
Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420
[TBL] [Abstract][Full Text] [Related]
58. Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
Michelsen L; Sørensen JB
Anticancer Res; 2015 Nov; 35(11):6255-9. PubMed ID: 26504059
[TBL] [Abstract][Full Text] [Related]
59. Intraoperative intracavitary hyperthermic chemotherapy for malignant pleural mesothelioma.
Okabe K
Ann Transl Med; 2017 Jun; 5(11):233. PubMed ID: 28706901
[TBL] [Abstract][Full Text] [Related]
60. Multimodal therapy of malignant pleural mesothelioma: is the replacement of radical surgery imminent?
Lindenmann J; Matzi V; Neuboeck N; Anegg U; Maier A; Smolle J; Smolle-Juettner FM
Interact Cardiovasc Thorac Surg; 2013 Mar; 16(3):237-43. PubMed ID: 23171517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
